整合性批量和单细胞转录组分析确定了与迁移体相关的lncRNA特征,可预测清细胞瘤的预后和免疫格局
Junlin Shen1, Chun Wang1, Mingpeng Zhang1
1Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Frontiers in immunology
|September 5, 2025
概括
这项研究发现了基于清细胞癌的长非编码RNAs (lncRNAs) 的新诊断特征. 这种特征预测患者的存活率,并揭示不同的瘤特征,为ccRCC提供新的治疗策略.
科学领域:
- 癌症学
- 分子生物学
- 基因组学
背景情况:
- 清细胞细胞癌 (ccRCC) 的复发和转移率很高,导致预后不佳.
- 迁移体和长非编码RNA (lncRNAs) 与瘤进展有关,但它们在ccRCC中的综合预后作用尚不清楚.
研究的目的:
- 识别与迁移体相关的 lncRNA 并构建ccRCC的预后风险特征.
- 评估该特征与整体存活率,瘤突变负担,瘤微环境,免疫逃避和药物敏感性的关联.
- 使用单细胞转录学探索细胞类型特异表达和细胞间通信网络.
主要方法:
- 使用癌症基因组图谱 (TCGA) 数据集来识别与迁移组相关的lncRNA并构建预后模型.
- 评估了风险特征与临床/基因特征之间的相关性,包括瘤微环境 (TME) 和免疫逃避.
- 进行单细胞转录组分析和体外实验以验证关键的 lncRNA 功能.
主要成果:
- 构建的风险特征显著地将ccRCC患者分为高风险和低风险组,具有不同的生存结果.
- 高风险患者的瘤突变负担 (TMB) 高,免疫规避能力强.
- 单细胞分析显示了与特征相关的细胞异质性和TME特征,FOXD2-AS1抑制了瘤的进展.
结论:
- 一种新的与迁移体相关的 lncRNA 风险特征对ccRCC具有显著的预后和治疗潜力.
- 这种特征有效地捕捉了ccRCC的独特免疫,基因组和药理特征.
- 关键的 lncRNA 可能通过迁移体介导途径驱动ccRCC的进展,需要进一步的机制研究.
相关概念视频
lncRNA - Long Non-coding RNAs
8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
Non-LTR Retrotransposons
11.8K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.8K


